News Releases & Statements
News Releases & Statements
The Leukemia & Lymphoma Society Launches National Patient Registry to Answer Crucial COVID-19 Questions for Blood Cancer Patients
Posted On: February 17, 2021RYE BROOK, N.Y., Feb. 17, 2021 – The Leukemia & Lymphoma Society (LLS) announced today a collaboration with Ciitizen, a digital health technology startup, to collect data on the impact of COVID-19 and vaccination from people with a current or past diagnosis of blood cancer as part of a broader strategic partnership. Read More
New Drug Approval Expands Options for Patients with Triple-Class Refractory Multiple Myeloma
Posted On: February 11, 2021Update: October 25, 2021
Read More
The Leukemia & Lymphoma Society Joins CURE Media Group's Strategic Alliance Partnership Program
Posted On: February 11, 2021CURE Media Group, the industry-leading multimedia platform devoted to cancer updates and research that reaches more than 1 million patients, survivors and caregivers, announces the addition of The Leukemia & Lymphoma Society (LLS) to its Strategic Alliance Partnership (SAP) program.
Read More
New Drug Approval Expands Options For Patients with Rare Marginal Zone Lymphoma and Advanced Follicular Lymphoma
Posted On: January 25, 2021Rye Brook, N.Y., February 5, 2021 – The U.S. Food and Drug Administration (FDA) today announced approval of UKONIQ™ (umbralisib), a once-daily, oral medication for the treatment of marginal zone lymphoma (MZL) that has returned or worsened following prior treatment with an anti-CD20 antibody. MZL is a clinical heterogeneous, slow-growing non-hodgkin lymphoma composed of three subtypes: extranodal, nodal or splenic MZL. It is considered a slow growing disease with generally favorable outcome. Read More
FDA Approval: Treatment Advance for Patients with Rare Blood Cell Disorder
Posted On: January 19, 2021Rye Brook, N.Y., January 19, 2021 – On January 15, the U.S. Food and Drug Administration (FDA) announced approval of daratumumab plus hyaluronidase (Darzalex Faspro®) for adults with newly diagnosed light chain (AL) amyloidosis, a rare and serious blood cell disorder that may occur by itself or with myeloma. Daratumumab is used in combination with chemotherapy agents bortezomib (Velcade®) and cyclophosphamide (Cytoxan® or Neosar®), plus the corticosteroid dexamethasone in these patients.
Read More
The Leukemia & Lymphoma Society Applauds Bipartisan Agreement to Stop Surprise Medical Bills
Posted On: December 21, 2020Rye Brook, NY (December 21, 2020) - The Leukemia & Lymphoma Society issues the following statement in response to Congress including policies designed to protect patients from surprise medical bills in the stimulus bill scheduled for a vote Monday, Dec. 21, 2020:
LLS applauds Congress for reaching a bipartisan agreement that will, after years of work, hold patients harmless from surprise medical bills.
Read More
FDA APPROVAL: TREATMENT ADVANCE FOR PATIENTS WITH MULTIPLE MYELOMA
Posted On: December 18, 2020Rye Brook, N.Y. (December 18, 2020) – The U.S. Food and Drug Administration (FDA) today announced approval of selinexor (Xpovio®) for adults with multiple myeloma who have had at least one prior type of treatment. Selinexor is used in combination with the chemotherapy drug bortezomib (Velcade®) and the corticosteroid dexamethasone in these patients.
Read More
The Leukemia & Lymphoma Society Statement on COVID-19 Vaccine Distribution
Posted On: December 14, 2020At The Leukemia & Lymphoma Society (LLS), we hear from blood cancer patients and caregivers each day about the profound effects of the COVID-19 pandemic on their cancer care, treatment, and daily lives. As a patient-focused leader in the scientific and medical community, we are encouraged by the U.S. Food & Drug Administration (FDA) decision to grant emergency use authorization (EUA) to the first COVID-19 vaccine in the U.S.
Read MoreMedia Requests
Please send all media-related inquiries and interview requests to mediarelations@lls.org. An LLS representative will respond as soon as possible.